I

Immunic Therapeutics

Clinical-stage biopharma developing oral autoimmune therapies

Senior Manager - Financial Planning & Analysis

Corporate Finance & FP&APosted on Nov 10
Full-timeGräfelfing, GermanyNo salary listedHybrid

About the Job

Requirements

  • A degree in Finance, Accounting, Business Administration, Economics, or a related field, or equivalent experience is required.
  • At least 7 years of relevant Finance or FP&A experience is required; pharma, biotech, or life-sciences experience is ideal.
  • Strong experience in budgeting, forecasting, financial modeling, variance analysis, and management reporting is required.
  • Experience serving as a Finance Business Partner to non-finance stakeholders and translating complex operational plans into financial forecasts and actionable insights is required.
  • Advanced Excel and financial modeling skills are required, along with experience using ERP, planning, and business-intelligence systems.
  • Strong analytical capabilities, attention to detail, and the ability to understand financial details and the strategic big picture are required.
  • Excellent communication and stakeholder-management skills are required, including the confidence to constructively challenge assumptions and present financial implications to senior management.
  • Ability to work effectively in a fast-paced, international, cross-functional biotech environment while balancing strategic work and hands-on execution is required.
  • Fluent English is required.

Responsibilities

  • Lead financial planning, forecasting, and performance management for Vidofludimus Calcium, including budgets, long-range plans, forecasts, and scenario analyses.
  • Develop and maintain an integrated program financial model that translates clinical, CMC, regulatory, and other development plans into expected cash expenditures.
  • Partner with Clinical Development Operations, CMC, Regulatory, Medical, and Preclinical teams to challenge assumptions and build reliable financial forecasts.
  • Drive clinical-trial budgeting and forecasting, including costs for CROs, laboratories, investigator sites, drug supply, and other significant external expenses.
  • Monitor actual and committed spending against budgets and forecasts, analyze variances, and proactively identify financial risks and opportunities.
  • Build and maintain transparent financial reporting for program spending, forecasts, commitments, variances, and key cost drivers for relevant stakeholders.
  • Review vendor contracts, proposals, change orders, and work orders financially, and support commercial negotiations with CROs and other key development partners.
  • Support the quarterly close process, including inputs for clinical and other development-related accruals.
  • Provide senior management with financial analysis and decision support covering program costs, cash requirements, forecast changes, scenarios, and key financial drivers.
  • Support group-wide FP&A activities and continuous process improvement, including corporate budgeting, long-range planning, management and Board reporting, financial models, and reporting tools.

Desired Qualifications

  • Prior experience with clinical-development budgeting, CRO financial management, clinical-trial accruals, or pharmaceutical R&D FP&A is preferred.
  • German language skills are advantageous.

About the Company

Immunic Therapeutics

Clinical-stage biopharma developing oral autoimmune therapies

Immunic Therapeutics develops oral therapies for chronic inflammatory and autoimmune diseases and is in clinical-stage development. Its lead candidate, vidofludimus calcium (IMU-838), is an oral small molecule that activates the Nurr1 receptor to protect nerve cells and inhibits DHODH to calm overactive immune responses; its pipeline also includes IMU-856, a SIRT6 modulator aimed at restoring intestinal barrier function, with IMU-381 in preclinical GI programs. The company emphasizes oral, small-molecule drugs with dual actions and pursues partnerships or licensing for commercialization rather than relying on near-term product revenue. Its goal is to advance its drug candidates through clinical trials toward commercialization, potentially via collaborations with larger pharma companies.

Company size
51-200
Company stage
IPO
Headquarters
New York City, New York
Founded
2016

Recently Posted Jobs

Explore more opportunities at Immunic Therapeutics

See more jobs